A Phase I Study of Entinostat in combination with Enzalutamide for treatment of patients with castration-resistant prostate cancer (CRPC)


  1. Determine the safe dose of Entinostad when given in combination with Enzalutamide in CRPC patients
  2. Determine the safety profiles of the combination of Entinostat and Enzalutamide

Candidates: Patients with Castration-Resistant Prostate Cancer will participate in this phase I study by taking enzalutamide daily and the study drug Entinostat once every 7 days.

Clinical Program: Urological Oncology Program
Cancer Type & Condition: Prostate Cancer
Principal Investigator: Jianqing Lin
Contact Info: 2029940450